Scientia Ventures

knowledge is power

In short

Intelligent Investment in Healthcare

In Numbers

31 Companies Funded

5 IPOs



Latest Press

Scientia Ventures Portfolio Company, Royalty Pharma, Surges On Public Debut

New Ventures Portfolio Company, ADC Therapeutics, Completes $267 Million IPO

FDA Approves Intra-Cellular Therapies’ Novel Antipsychotic, CAPLYTA® (lumateperone) for the Treatment of Schizophrenia in Adults

FibroGen Submits New Drug Application to the U.S. FDA for Roxadustat in Patients With Anemia of Chronic Kidney Disease

Cibus Achieves Critical Milestones for Two New Gene-Edited Traits that Increase Productivity for Rice Farmers


Royalty Pharma

Transforming the funding of life sciences through collaborative capital, Royalty Pharma developed and is the leader in the pharmaceutical royalty business.


ADC Therapeutics

ADC Therapeutics is focused on the development of proprietary Antibody Drug Conjugates for the treatment of both solid and hematological cancers.


Intra-Cellular Therapies

Intra-Cellular Therapies is a leading biopharmaceutical company founded by Nobel Prize winner: Paul Greengard...